LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Search

BioCryst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

7.62 -0.13

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.55

Максимум

7.62

Ключови измерители

By Trading Economics

Приходи

5.1M

5.1M

Продажби

18M

163M

Марж на печалбата

3.113

Служители

580

EBITDA

7.2M

28M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+129.36% upside

Дивиденти

By Dow Jones

Следващи печалби

3.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-172M

1.7B

Предишно отваряне

7.75

Предишно затваряне

7.62

Настроения в новините

By Acuity

50%

50%

132 / 371 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.09.2025 г., 18:25 ч. UTC

Значими двигатели на пазара

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27.09.2025 г., 07:00 ч. UTC

Печалби

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27.09.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

26.09.2025 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26.09.2025 г., 20:54 ч. UTC

Печалби

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

26.09.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26.09.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

26.09.2025 г., 19:54 ч. UTC

Пазарно говорене

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26.09.2025 г., 19:53 ч. UTC

Придобивния, сливания и поглъщания

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26.09.2025 г., 19:40 ч. UTC

Печалби

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26.09.2025 г., 19:24 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26.09.2025 г., 19:17 ч. UTC

Пазарно говорене

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26.09.2025 г., 19:15 ч. UTC

Пазарно говорене

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

26.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26.09.2025 г., 18:50 ч. UTC

Пазарно говорене
Печалби

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26.09.2025 г., 18:36 ч. UTC

Пазарно говорене

Silver Closes Out Week With Strong Surge -- Market Talk

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: Global Development Hasn't Received All Necessary Approvals >ING

26.09.2025 г., 18:02 ч. UTC

Придобивния, сливания и поглъщания

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26.09.2025 г., 17:54 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26.09.2025 г., 16:56 ч. UTC

Пазарно говорене
Печалби

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26.09.2025 г., 16:41 ч. UTC

Пазарно говорене
Печалби

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26.09.2025 г., 16:26 ч. UTC

Печалби

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

26.09.2025 г., 16:12 ч. UTC

Пазарно говорене

Nike Stock Seen With Limited Upside -- Market Talk

26.09.2025 г., 15:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

26.09.2025 г., 15:59 ч. UTC

Пазарно говорене

Nike Seen Showing Progress in Turnaround -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

129.36% нагоре

12-месечна прогноза

Среден 17.5 USD  129.36%

Висок 30 USD

Нисък 12 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Настроение

By Acuity

132 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat